TP53 and breast cancer: In terms of the patient outcome, CDK2/p53 co-expression influences the survival outcome (overall p = 0.01) (Figure 2E), and this association was maintained in luminal BC (Supplementary Figure S2A) and in endocrine-therapy-treated patients (Supplementary Figure S2B).